À̹ÌÁö È®´ë GC Pharma, a South Korean biopharmaceutical company, has established a new vaccine development unit, Curevo, Inc., in the United States in order to facilitate its clinical and regulatory entry into the world¡¯s largest pharmaceutical market.
The Seattle-based entity will support GC Pharma¡¯s next-generation vaccine development activities and the launch of a premium vaccine for herpes zoster, according to industry sources on Monday. GC Pharma owns an 81.4 percent in the new entity.
Curevo has a plan to launch a clinical trial in the U.S. this year for CRV-101, an investigational shingles vaccine jointly developed by GC Pharma and the Mogam Institute for Biomedical Research in Korea.
The clinical study will be conducted under the partnership between Curevo and U.S.-based Infectious Disease Research Institute (IDRI).
It is the first time that GC Pharma involved itself directly in the development of a premium vaccine. The company has marketed a shingles vaccine developed by Merck & Co. across Korea.
Besides the shingles vaccine, Curevo¡¯s pipeline also includes a chickenpox vaccine and a respiratory syncytial virus (RSV) vaccine.
By Kim Hye-soon and Minu Kim
[¨Ï Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]